XML 61 R54.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information - Schedule of Reconciliation of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                
Total external R&D program expenses $ (4,785)     $ 17,313     $ 30,234 $ 49,838
Total internal R&D expenses 497     10,272     16,180 32,159
Total R&D expenses (4,288)     27,585     46,414 81,997
Total G & A expenses 8,254     6,513     23,292 20,411
Total restructuring expenses             17,486  
Other segment (income) expense [1] (260)     (2,339)     (2,367) (8,168)
Segment net loss 3,706 $ 47,982 $ 33,137 31,759 $ 31,564 $ 30,917 84,825 94,240
ARTISTRY-6                
Segment Reporting Information [Line Items]                
Total external R&D program expenses (4,802)     3,075     3,898 6,907
ARTISTRY-7                
Segment Reporting Information [Line Items]                
Total external R&D program expenses (71)     4,801     4,778 15,591
Early Discovery Programs                
Segment Reporting Information [Line Items]                
Total external R&D program expenses 11     700     5,341 2,142
Employee-Related                
Segment Reporting Information [Line Items]                
Total internal R&D expenses 493     7,635     12,386 24,143
Total G & A expenses 980     3,443     6,823 11,170
Total restructuring expenses             9,457  
Other External R&D Program Expenses                
Segment Reporting Information [Line Items]                
Total external R&D program expenses [2] 77     8,737     16,217 25,198
Other Internal R&D Expenses                
Segment Reporting Information [Line Items]                
Total internal R&D expenses [3] 4     2,637     3,794 8,016
Other G&A expenses                
Segment Reporting Information [Line Items]                
Total G & A expenses [4] $ 7,274     $ 3,070     16,469 $ 9,241
Other restructuring expenses                
Segment Reporting Information [Line Items]                
Total restructuring expenses [5]             $ 8,029  
[1] Other non-operating (income) expense included in segment net loss includes interest income, tax expense, and other non-operating income and expense.

During the three months ended September 30, 2025, the Company and one of its CROs completed the review and reconciliation of the costs incurred during the ARTISTRY-6 trial following the close-out of all clinical trial sites, concluding that actual costs incurred were approximately $4.8 million less than estimated over the course of the trial. The reduction in the estimated costs incurred during the ARTISTRY-6 trial was recorded as a change in estimate during the three months ended September 30, 2025 as a credit to R&D expense.
[2] Other external R&D program expenses included in segment net loss include expenses related to other clinical trials and general external program expenses.
[3] Other internal R&D expenses included in segment net loss include expenses related to occupancy and depreciation.
[4] Other G&A expenses included in segment net loss include expenses related to professional fees, information technology, depreciation, and other general G&A expenses.
[5] Other restructuring expenses include contract termination costs, impairment and asset write-offs incurred in connection with our reduction-in-force and the termination of certain development programs.